ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NKBP China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM)

5.54
0.00 (0.00%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) NASDAQ:NKBP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.54 0 01:00:00

Rosen Law Firm Announces Investigation of China Nuokang Bio-Pharmaceutical In Connection With Going Private Proposal from Kin...

06/10/2012 5:11pm

Business Wire


China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) Charts.

The Rosen Law Firm is investigating the Board of Directors of China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) for possible breaches of fiduciary duty and other violations of corporate law in connection with a going private proposal from Kingbird Investment Inc., beneficially owned by Ms. Yuhuan Zhu – the wife of Nuokang's Chairman and CEO, Mr. Baizhong Xue.

If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the proposal, offered by Kingbird Investment, shareholders will receive $5.80 for each American Depository Share (“ADS”) or $0.725 for each common share of Nuokang they own. The investigation relates to whether the proposal for $5.80/ADS is fair to public shareholders and whether Nuokang’s Board fiduciary duties in connection with the offer.

If you own shares of Nuokang and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

1 Year China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) Chart

1 Year China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) Chart

1 Month China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) Chart

1 Month China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) Chart

Your Recent History

Delayed Upgrade Clock